Protocol Ledger

NCT05031780 · Phase II/III · ACTIVE NOT RECRUITING

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Interventional Phase II/III clinical trial protocol NCT05031780 sponsored by Agios Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-11 Enrollment: 286 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05031780
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)286 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05031780
Protocol FieldVerified Registry Value
NCT IdentifierNCT05031780
Consolidated Lead SponsorAgios Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment286 participants (ACTUAL)
Registered Start Date2022-02-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI